Publication

Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network

Bibliographic Details
Summary:Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists.Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed.Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%).Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists.Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.
Authors:NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
Subject:Portugal SDG 3 - Good Health and Well-being Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents; Portugal; Primary Health Care; Sentinel Surveillance Sentinel Surveillance Diabetes Mellitus, Type 2/drug therapy Cuidados de Saúde Primários; Diabetes Mellitus Tipe 2/tratamento; Hipoglicemiantes; Portugal; Vigilância de Evento Sentinela Medicine(all) Hypoglycemic Agents Primary Health Care
Year:2019
Country:Portugal
Document type:journal article
Identifiers:ID: PURE: 14019296
Access type:Open
Associated institution:Acta Médica Portuguesa, Repositório Institucional da UNL, RUN
Funded project code:PURE: 14019296
Language:English
Origin:Acta Médica Portuguesa
_version_ 1850560626020057088
author2 NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
author_facet NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
conditionsOfAccess_str open access
contentURL_str_mv https://run.unl.pt/bitstream/10362/76914/1/10414_44964_2_PB.pdf
country_str PT
description Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists.Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed.Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%).Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists.Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.
documentTypeURL_str http://purl.org/coar/resource_type/c_6501
documentType_str journal article
id 4fcaa90f-cc1e-4e27-a1d4-fd06631768f2
identifierDoi_str https://doi.org/10.20344/amp.10414
identifierOther_str PURE: 14019296
language eng
publicationDateFull_str 2019-07-29T22:40:36Z
publicationDate_str 2019-07-29
publishDate 2019
relatedInstitutions_str_mv Acta Médica Portuguesa
Repositório Institucional da UNL
RUN
resourceName_str Acta Médica Portuguesa
spellingShingle Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
Portugal
SDG 3 - Good Health and Well-being
Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents; Portugal; Primary Health Care; Sentinel Surveillance
Sentinel Surveillance
Diabetes Mellitus, Type 2/drug therapy
Cuidados de Saúde Primários; Diabetes Mellitus Tipe 2/tratamento; Hipoglicemiantes; Portugal; Vigilância de Evento Sentinela
Medicine(all)
Hypoglycemic Agents
Primary Health Care
title Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
topic Portugal
SDG 3 - Good Health and Well-being
Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents; Portugal; Primary Health Care; Sentinel Surveillance
Sentinel Surveillance
Diabetes Mellitus, Type 2/drug therapy
Cuidados de Saúde Primários; Diabetes Mellitus Tipe 2/tratamento; Hipoglicemiantes; Portugal; Vigilância de Evento Sentinela
Medicine(all)
Hypoglycemic Agents
Primary Health Care